

*This content has neither been reviewed nor approved by MCG Health.*

## SHP Galectin 3 (LGALS3)

AUTH: SHP Medical 304 v3 (AC)

**MCG Health**  
Ambulatory Care  
26th Edition

[Link to Codes](#)

- [Coverage](#)
- [Application to Products](#)
- [Authorization Requirements](#)
- [Description of Item or Service](#)
- [Exceptions and Limitations](#)
- [Clinical Indications for Procedure](#)
- [Document History](#)
- [Coding Information](#)
- [References](#)
- [Codes](#)

---

### Coverage

[Return to top of SHP Galectin 3 \(LGALS3\) - AC](#)

See the appropriate benefit document for specific coverage determination. Member specific benefits take precedence over medical policy.

---

### Application to Products

[Return to top of SHP Galectin 3 \(LGALS3\) - AC](#)

Policy is applicable to all products.

---

### Authorization Requirements

[Return to top of SHP Galectin 3 \(LGALS3\) - AC](#)

Pre-certification by the Plan is required.

---

### Description of Item or Service

[Return to top of SHP Galectin 3 \(LGALS3\) - AC](#)

Galectin 3 (LGALS3) is a protein that is involved with cell growth, cell death, cell division cycle, cell adhesions and other cell functions. Mutations are associated with heart disease, stroke, cancer, fibrosis and inflammation.

---

### Exceptions and Limitations

[Return to top of SHP Galectin 3 \(LGALS3\) - AC](#)

There is insufficient scientific evidence to support the medical necessity of this service as it is not shown to improve health outcomes upon technology review.

---

### Clinical Indications for Procedure

[Return to top of SHP Galectin 3 \(LGALS3\) - AC](#)

- NA

---

### Document History

[Return to top of SHP Galectin 3 \(LGALS3\) - AC](#)

- Revised Dates:
  - 2020: January
  - 2016: January, April
  - 2015: January, February, October
  - 2014: July, December
  - 2013: January, February, March, July, August, September
- Reviewed Dates:
  - 2022: June
  - 2021: August
  - 2020: August
  - 2019: May
  - 2018: May
  - 2016: June, July
- Effective Date: December 2012

---

### Coding Information

[Return to top of SHP Galectin 3 \(LGALS3\) - AC](#)

- CPT/HCPCS codes covered if policy criteria is met:
  - None
- CPT/HCPCS codes considered not medically necessary per this Policy:
  - CPT 82777 - Galectin-3

---

### References

[Return to top of SHP Galectin 3 \(LGALS3\) - AC](#)

References used include but are not limited to the following:

Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; Uptodate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2021, Jun 07). Retrieved Jun 06, 2022, from MCG: <https://careweb.careguidelines.com/ed25/index.html>

(2022). Retrieved Jun 06, 2022, from Hayes, Inc: <https://evidence.hayesinc.com/search?q=%257B%2522text%2522:%2522Galectin%25203%2522,%2522title%2522:null,%2522termsource%2522:%2522searchbar%2522,%2522page%2522:%257B%2522page%2522:0,%2522size%2522:50%257D,%2522type%2522:%2522all%2522,%2522sources%2522:%2522>

(2022). Retrieved Jun 06, 2022, from UpToDate: [https://www.uptodate.com/contents/search?search=galectin%203&sp=0&searchType=PLAIN\\_TEXT&source=USER\\_INPUT&searchControl=TOP\\_PULLDOWN&searchOffset=1&autoComplete=true&language=&max=0&index=0~1&autoCompleteTerm=Galectin%20&rawSentence=](https://www.uptodate.com/contents/search?search=galectin%203&sp=0&searchType=PLAIN_TEXT&source=USER_INPUT&searchControl=TOP_PULLDOWN&searchOffset=1&autoComplete=true&language=&max=0&index=0~1&autoCompleteTerm=Galectin%20&rawSentence=)

(2022). Retrieved Jun 06, 2022, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/search-results.aspx?keyword=Galectin+3&keywordType=starts&areald=s53&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all>

(2022). Retrieved Jun 06, 2022, from AIM Specialty Health: <https://aimguidelines.wpengine.com/no-search-results-found/>

(2022). Retrieved Jun 06, 2022, from National Comprehensive Cancer Network: <https://www.nccn.org/search-result?indexCatalogue=nccn-search-index&searchQuery=Galectin&wordsMode=AllWords>

(2022). Retrieved Jun 06, 2022, from Google, Inc: [https://www.google.com/search?q=professional+recommendations+for+galectin-3&rlz=1C1GCEA\\_enUS982US982&oq=professional+recommendations+for+Galec&aqs=chrome.1.69i57j33i160i4.17004j0j4&sourceid=chrome&ie=UTF-8](https://www.google.com/search?q=professional+recommendations+for+galectin-3&rlz=1C1GCEA_enUS982US982&oq=professional+recommendations+for+Galec&aqs=chrome.1.69i57j33i160i4.17004j0j4&sourceid=chrome&ie=UTF-8)

Boutin, L., Legrand, M., Sadoune, M., Mebazaa, A., Gayat, E., Chadjichristos, C., & Depret, F. (2022, Jan 06). Elevated plasma Galectin-3 is associated with major adverse kidney events and death after ICU admission. Retrieved Jun 06, 2022, from PubMed: <https://pubmed.ncbi.nlm.nih.gov/34991653/>

Natriuretic Peptide and Biomarkers Testing for Heart Failure. (2020, May 01). Retrieved Jun 06, 2022, from DynaMed: [https://www.dynamedex.com/evaluation/natriuretic-peptide-and-biomarkers-testing-for-heart-failure#GALECTIN\\_3](https://www.dynamedex.com/evaluation/natriuretic-peptide-and-biomarkers-testing-for-heart-failure#GALECTIN_3)

Procedure Fee Files & CPT Codes. (2022). Retrieved Jun 06, 2022, from Department of Medical Assistance Services: <https://www.dmas.virginia.gov/for-providers/rates-and-rate-setting/procedure-fee-files-cpt-codes/#searchCPT>

Nakajima, K., Balan, V., & Raz, A. (2020, Sep 14). Galectin-3: an immune checkpoint target for musculoskeletal tumor patients. Retrieved Aug 02, 2021, from PubMed: <https://pubmed.ncbi.nlm.nih.gov/32929561/>

Ram, T., Lekshmi, A., Somanathan, T., & Sujathan, K. (2021). Galectin-3: A factotum in carcinogenesis bestowing an archery for prevention. Retrieved Aug 02, 2021, from PubMed: <https://pubmed.ncbi.nlm.nih.gov/33998569/>

---

## Codes

[Return to top of SHP Galectin 3 \(LGALS3\) - AC](#)

**CPT® : 82777**

*CPT copyright 2021 American Medical Association. All rights reserved.*

---

MCG Health  
Ambulatory Care 26th Edition